Gonadotropin-releasing hormone analog treatment for the prevention of treatment-related ovarian failure and infertility in women of reproductive age with Hodgkin lymphoma

References

• Sklar C. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr 2005; 34: 25–27
   PubMedGoogle Scholar
• Byrne J. Infertility and premature menopause in childhood cancer survivors. Med Pediatr Oncol 1999; 33: 24–28
   PubMedGoogle Scholar
• Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005; 23: 7555–7564
   PubMed Web of Science ®Google Scholar
• De Bruin M L, Huisbrink J, Hauptmann M, Kuenen M A, Quvens G M, van't Veer M B, et al. Treatment-related risk factors for premature menopause following Hodgkin's lymphoma. Blood 2008; 111: 101–108
   PubMed Web of Science ®Google Scholar
• Haukvik U K, Dieset I, Bjoro T, Holte H, Fosså S D. Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma. Ann Oncol 2006; 17: 1428–1433
   PubMed Web of Science ®Google Scholar
• Wallace W H, Anderson R A, Irvine D S. Fertility preservation for young patients with cancer: who is at risk and what can be offered. Lancet Oncol 2005; 6: 209–218
   PubMed Web of Science ®Google Scholar
• Gougeon A. Dinamics of follicular growth in the human: a model from preliminary results. Hum Reprod 1986; 1: 81–87
   PubMed Web of Science ®Google Scholar
• Lee S J, Schover L R, Partridge A H, Patrizio P, Wallace W H, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917–2931
   PubMed Web of Science ®Google Scholar
• Warne G L, Fairley K F, Hobbs J B, Martin F I. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973; 289: 1159–1162
   PubMed Web of Science ®Google Scholar
• Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoky Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977; 39: 1403–1409
   PubMed Web of Science ®Google Scholar
• Kreuser E D, Felsenberg D, Behles C, Seibt-Jung H, Mielcarek K, Diehl V, et al. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 1992; 3(Suppl 4)105–110
   PubMedGoogle Scholar
• Fosså S D, Magelssen H. Fertility and reproduction after chemotherapy of adult cancer patients: malignant lymphoma and testicular cancer. Ann Oncol 2004, Suppl 4: 259–265
   Google Scholar
• Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007; 110: 2222–2229
   PubMed Web of Science ®Google Scholar
• Wallace W H, Thomson A B, Saran F, Kelsey T W. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005; 62: 738–744
   PubMed Web of Science ®Google Scholar
• Horning S J, Hoppe R T, Kaplan H S, Rosenberg S A. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 1981; 304: 1377–1382
   PubMed Web of Science ®Google Scholar
• Aisner J, Wiernik P H, Pearl P. Pregnancy outcome in patients treated for Hodgkin's disease. J Clin Oncol 1993; 11: 507–512
   PubMed Web of Science ®Google Scholar
• Hodgson D C, Pintilie M, Gitterman L, Dewitt B, Buckley C A, Ahmed S, et al. Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 2007; 25: 11–15
   PubMed Web of Science ®Google Scholar
• Damewood M D, Hesla H S, Lowen M, Schultz M J. Induction of ovulation and pregnancy following lateral oophoropexy for Hodgkin's disease. Int J Gynaecol Obstet 1990; 33: 369–371
   PubMed Web of Science ®Google Scholar
• Pereyra P B, Mendez R JM, Milone G, Fernandez I, Kvicala R, Mila T, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001; 81: 391–397
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist co-treatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007; 12: 1044–1054
   PubMed Web of Science ®Google Scholar
• Ataya K, Rao L V, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995; 52: 365–372
   PubMed Web of Science ®Google Scholar
• Sklar C A, Mertens A C, Mitby P, Whitton J, Stovall M, Kasper C, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006; 98: 890–896
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Nomdedeu B, Camus A, Mercadal S, Martinez de Osaba M J, Balasch J. Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril 2007; 87: 702–705
   PubMed Web of Science ®Google Scholar
• Recchia F, Sica G, De Filippis S, Saggio G, Rosselli M, Rea S. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Drugs 2002; 13: 417–424
   PubMed Web of Science ®Google Scholar
• Franchi-Rezgui P, Rousselot P, Espié M, Brière J, Pierre Marolleau J, Gisselbrecht C, et al. Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas. Hematol J 2003; 4: 116–120
   PubMedGoogle Scholar
• Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe J M, Dann E J. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin's lymphoma. Fertil Steril 2008; 89: 166–173
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996; 11: 1620–1626
   PubMed Web of Science ®Google Scholar
• Chapman R M, Sutcliffe S B, Malpas J S. Cytotoxic-induced ovarian failure in women with Hodgkin's disease I. Hormone function. JAMA 1979; 242: 1877–1881
   PubMed Web of Science ®Google Scholar
• Oktay K, Sonmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing ormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 2007; 12: 1055–1066
   PubMed Web of Science ®Google Scholar
• Kitajima Y, Endo T, Nagasawa K, Manase K, Honnma H, Baba T, et al. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology 2006; 147: 694–699
   PubMed Web of Science ®Google Scholar
• Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest 2007; 63: 102–106
   PubMed Web of Science ®Google Scholar
• Morita Y, Perez G I, Paris F, Miranda S R, Ehleiter D, Haimovitz-Friedman A, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 2000; 6: 1109–1114
   PubMed Web of Science ®Google Scholar
• Behringer K, Wildt L, Haverkamp H, Diehl V, Pfistner B, Engert A, et al. Results of the randomized phase II trial for the reduction of ovarian failure with the use of GnRH-analogues and oral contraceptives in young women (18–40 years) treated with intensive chemotherapy for advanced-stage Hodgkin lymphoma. Haematologica 2007; 92(Suppl 5)63–64
   Google Scholar
• Phase III Trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer. Available from: http://www.clinicaltrials.gov/ct/show/NCT00068601 [accessed 11.01.08]
   Google Scholar
• Prevention of chemotherapy-induced menopause by temporary ovarian suppression with triptorelin vs. control in young breast cancer patients. A randomized phase III multicenter study. Available from: http://www.clinicaltrials.gov/ct/show/NCT00311636 [accessed 11.01.08]
   Google Scholar
• Demeestere I, Simon P, Emiliani S, Delbaere A, Englert Y. Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin's disease. Oncologist 2007; 12: 1437–1442
   PubMed Web of Science ®Google Scholar
• Oktay K, Cil A P, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril 2006; 86: 70–80
   PubMed Web of Science ®Google Scholar
• Donnez J, Dolmans M M, Demylle D, Jadoul P, Pirard C, Squifflet J, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 364: 1405–1410
   PubMed Web of Science ®Google Scholar
• Meirow D, Levron J, Eldar-Geva T, Hardan I, Fridman E, Zalel Y, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005; 353: 318–321
   PubMed Web of Science ®Google Scholar
• Shaw J M, Bowels J, Koopman P. Fresh and cryopreserved ovarian tissue samples from donors with lymphoma transmit the cancer to the graft recipient. Hum Reprod 1996; 11: 1668–1673
   PubMed Web of Science ®Google Scholar
• Gosden R G, Rutherford A J, Norfolk D R. Debate: ovarian banking for cancer patients-transmission of malignant cells in ovarian grafts. Hum Reprod 1997; 12: 403
   PubMed Web of Science ®Google Scholar
• Seshadri T, Gook D, Lade S, Spencer A, Grigg A, Tiedemann K, et al. Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. Br J Cancer 2006; 94: 1007–1010
   PubMed Web of Science ®Google Scholar